MSD
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
August 7, 2024Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …
Merck shares data from phase 3 trial of Keytruda for gastric cancers
May 2, 2024Research and Development Gastric, MSD, Merck, Oncology, keytruda
Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …
Merck to acquire Harpoon Therapeutics for approximately $680m
January 10, 2024Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …
Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics
December 20, 2023Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin
Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …
Merck to acquire Caraway Therapeutics for up to $610m
November 22, 2023Business Services Caraway Therapeutics, MSD, Merck, Pharmacy, acquisition
Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced that they have entered into …
FDA approves Merck’s Keytruda for gastric cancer treatment
November 17, 2023Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda
Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …
Merck shares data from phase 3 trial for breast cancer treatment
August 1, 2023Research and Development MSD, Merck, Oncology, breast cancer, keytruda
Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …
AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment
June 9, 2023Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma
UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …
MSD announce new data from advanced renal cell carcinoma trial
June 8, 2021Manufacturing and Production MSD, rcc
Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …
NICE rejects Merck Serono’s Bavencio for urothelial cancer
May 10, 2021Sales and Marketing MSD, Merck, NHS, NICE, cancer treatment, pharma, pharma news
The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by …
Merck kidney and uterus cancer treatments granted priority review by FDA
May 7, 2021Medical Communications FDA, MSD, Merck, cancer treatment, kidney cancer treatment, pharma, pharma news, uterus cancer treatment
The FDA has granted priority review for Merck (MSD) and Eisai’s application for two new approvals for the combination of …
Merck cease development of $425 million COVID-19 treatment
April 16, 2021Medical Communications COVID-19, MSD, Merck, covid-19 treatment, pharma, pharma news
Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.
NHS agrees on MSD interim colorectal cancer treatment
March 25, 2021COVID-19, Cancer, MSD, NHS
MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …
AstraZeneca & MSD ovarian cancer drug combination approved by NICE
March 19, 2021Medical Communications AstraZeneca, MSD, NICE, oncology
A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …
Gilead and MSD partner to develop and commercialise two-drug HIV regimen
March 16, 2021Manufacturing and Production Gilead, HIV, MSD
Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …
